Selective miRNA inhibition in CD8+ cytotoxic T lymphocytes enhances HIV-1 specific cytotoxic responses

Front Immunol. 2022 Sep 26:13:998368. doi: 10.3389/fimmu.2022.998368. eCollection 2022.

Abstract

miRNAs dictate relevant virus-host interactions, offering new avenues for interventions to achieve an HIV remission. We aimed to enhance HIV-specific cytotoxic responses-a hallmark of natural HIV control- by miRNA modulation in T cells. We recruited 12 participants six elite controllers and six patients with chronic HIV infection on long-term antiretroviral therapy ("progressors"). Elite controllers exhibited stronger HIV-specific cytotoxic responses than the progressors, and their CD8+T cells showed a miRNA (hsa-miR-10a-5p) significantly downregulated. When we transfected ex vivo CD8+ T cells from progressors with a synthetic miR-10a-5p inhibitor, miR-10a-5p levels decreased in 4 out of 6 progressors, correlating with an increase in HIV-specific cytotoxic responses. The effects of miR-10a-5p inhibition on HIV-specific CTL responses were modest, short-lived, and occurred before day seven after modulation. IL-4 and TNF-α levels strongly correlated with HIV-specific cytotoxic capacity. Thus, inhibition of miR-10a-5p enhanced HIV-specific CD8+ T cell capacity in progressors. Our pilot study proves the concept that miRNA modulation is a feasible strategy to combat HIV persistence by enhancing specific cytotoxic immune responses, which will inform new approaches for achieving an antiretroviral therapy-free HIV remission.

Keywords: HIV; cellular immunity; cytotoxicity; micro-RNA; non-coding RNA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes
  • HIV Infections*
  • HIV Seropositivity*
  • HIV-1*
  • Humans
  • Interleukin-4 / pharmacology
  • MicroRNAs* / genetics
  • MicroRNAs* / pharmacology
  • Pilot Projects
  • T-Lymphocytes, Cytotoxic
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • MicroRNAs
  • Tumor Necrosis Factor-alpha
  • Interleukin-4